About one-third of patients with recurrent epithelial ovarian cancer respond to a new treatment. In this test-specific episode of the "Answers From the Lab" podcast, Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' biomarker test (Mayo ID: AFOLR) identifies patients eligible for the new therapy.

"This is a relatively new FDA-approved test, so there are no other options to identify the biomarker," Dr. Shahi says. "That makes it a unique test that can benefit patients."

Immunohistochemistry staining detects the tumor-associated folate receptor alpha antigen, an attractive therapeutic target.

Nearly 70% of patients with epithelial ovarian cancer relapse after primary treatment with chemotherapy and surgery. "By testing for folate receptor expression, we can identify patients with epithelial ovarian cancer who may benefit from receptor-targeted therapy," Dr. Shahi says.

Listen to learn more about Mayo Clinic Laboratories' FOLR1 predictive assay.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

AFOLR    | Folate Receptor Alpha (FOLR1), Semi-Quantitative Immunohistochemistry, Manual

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less